Lonza Group (LZAGY) Price & Analysis

Lonza Group AG, along with its various affiliates, provides a comprehensive array of offerings for the pharmaceutical, biotechnology, and nutrition industries. Its global operations extend across Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and other international markets. The company's extensive activities are structured into four main divisions: Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients. The Biologics division specializes in the outsourced development and manufacturing of biopharmaceutical products. This encompasses both clinical and commercial production requirements, overseeing the entire product journey from initial drug substance creation to the final drug product formulation. The Small Molecules segment acts as an integrated service provider for the development and production of small molecule active pharmaceutical ingredients (APIs) and their intermediate compounds. It offers broad support to clients across all stages of design, advancement, and large-scale manufacturing. Lonza's Cell & Gene division is dedicated to developing innovative technologies and platforms that streamline and scale the manufacturing processes for cell and gene therapies. It also delivers expert contract development and manufacturing services, coupled with essential regulatory support, for a wide range of advanced treatments, including allogeneic and autologous cell therapies, exosome-based therapies, and viral vector gene therapies. Additionally, this segment supplies specialized raw materials and crucial technological solutions relevant to the cell and gene therapy, injectable drug, vaccine, and general bio-manufacturing sectors. The Capsules & Health Ingredients segment furnishes various encapsulation products, sophisticated dosage form solutions, and nutritional components to both pharmaceutical and nutraceutical customers. Founded in 1897, the company's primary corporate office is situated in Basel, Switzerland.